Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

CARDIOVASCULAR DISEASE

A novel treatment for heart failure targets myocardial fibrosis

Nature Medicine volume 27, pages 1343–1344 (2021)Cite this article

Subjects

A new trial suggests that pirfenidone, an approved treatment for idiopathic pulmonary fibrosis, may also reduce myocardial fibrosis in patients with heart failure who have a preserved left ventricular ejection fraction.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Pathways that lead to myocardial fibrosis.

References

  1. Lewis, G. A. et al. Nat. Med. https://doi.org/10.1038/s41591-021-01452-0 (2021).

    Article  Google Scholar 

  2. Cleland, J. G. F. et al. Eur. Heart J. 42, 2331–2343 (2021).

    Article  Google Scholar 

  3. Pellicori, P. et al. Eur. J. Heart Fail. https://doi.org/10.1002/ejhf.2220 (2021).

    Article  PubMed  Google Scholar 

  4. Pellicori, P. et al. Eur. J. Heart Fail. 22, 1711–1723 (2020).

    Article  CAS  Google Scholar 

  5. Pellicori, P. et al. Cardiovasc. Res. 116, 91–100 (2020).

    Article  CAS  Google Scholar 

  6. Cleland, J. G. F. et al. Eur. Heart J. 39, 26–35 (2018).

    Article  CAS  Google Scholar 

  7. Cleland, J. G. F. et al. Eur. Heart J. 42, 684–696 (2020).

    Article  Google Scholar 

  8. Gonzalez, A., Schelbert, E. B., Diez, J. & Butler, J. J. Am. Coll. Cardiol. 71, 1696–1706 (2018).

    Article  Google Scholar 

  9. Aimo, A. et al. Pharmacol. Res. 155, 104694 (2020).

    Article  CAS  Google Scholar 

  10. Lopez, B. et al. J. Am. Coll. Cardiol. 67, 251–260 (2016).

    Article  CAS  Google Scholar 

  11. Lopez, B. et al. Nat. Rev. Cardiol. 18, 479–498 (2021).

    Article  Google Scholar 

  12. Mason, T. et al. JACC Cardiovasc. Imaging 14, 1164–1173 (2021).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Robertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, Glasgow Royal Infirmary, Glasgow, UK

    John G. F. Cleland & Pierpaolo Pellicori

  2. Program of Cardiovascular Diseases, CIMA. Universidad de Navarra and IdiSNA, Pamplona, Spain

    Arantxa González

  3. CIBERCV, Carlos III Institute of Health, Madrid, Spain

    Arantxa González

Authors
  1. John G. F. Cleland
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pierpaolo Pellicori
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Arantxa González
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John G. F. Cleland.

Ethics declarations

Competing interests

J.G.F.C. has received research funding from Torrent Pharmaceuticals, which has an advanced glycation-end-product breaker in development.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cleland, J.G.F., Pellicori, P. & González, A. A novel treatment for heart failure targets myocardial fibrosis. Nat Med 27, 1343–1344 (2021). https://doi.org/10.1038/s41591-021-01457-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-021-01457-9

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research